ARTICLE
|
Product Development
Patient was in trial of the company’s limb-girdle muscular dystrophy gene therapyBy Steve Usdin, Washington Editor
July 17, 2025 11:51 PM UTC
A third patient, a 51 year-old in a Phase I study of SRP-9004 for limb-girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy.
Like two deaths associated with the company’s Duchenne muscular dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, the most recent death was caused by acute liver toxicity, Sarepta Therapeutics Inc. (NASDAQ:SRPT) spokesperson Tracy Sorrentino told BioCentury. …
